Abstract

Professor Jackson’s pioneering academic research has enabled the identification of many key principles by which cells respond to and repair DNA damage. Recognising that many DNA damage response proteins represent attractive drug targets, in 1997 Steve founded the drug-discovery company KuDOS Pharmaceuticals Ltd., then served as part-time Chief Scientific Officer (CSO) until and after its acquisition by AstraZeneca in 2006. In 2010, Steve founded Mission Therapeutics Ltd. (Babraham, Cambridge) to exploit recent advances in protein ubiquitylation and deubiquitylation to derive new medicines, particularly for cancer and neurodegenerative diseases, and serves as its part-time CSO . Professor Jackson will be sharing his experience and advice about translating academic research towards patient benefit.